Search

Bio-Techne Corp

Fechado

SetorSaúde

72.4 0.28

Visão Geral

Variação de preço das ações

24h

Atual

Mín

72.03

Máximo

72.25

Indicadores-chave

By Trading Economics

Rendimento

13M

51M

Vendas

16M

311M

P/E

Médio do Setor

103.029

57.002

EPS

0.51

Rendimento de Dividendos

0.44

Margem de lucro

16.392

Funcionários

3,100

EBITDA

21M

99M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

-1.86% downside

Dividendos

By Acuity

Rendimento de Dividendos

Médio do Setor

0.44%

2.22%

Próximos Ganhos

4 de nov. de 2026

Próxima data de dividendos

28 de ago. de 2026

Próxima data de ex-dividendo

24 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

2.7B

11B

Abertura anterior

72.12

Fecho anterior

72.4

Sentimento de Notícias

By Acuity

59%

41%

291 / 340 Ranking em Healthcare

Bio-Techne Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de ago. de 2026, 19:16 UTC

Correlated Moves
News

Bio-Techne Corp corrected its dividend record date to August 24, 2026. Shares are trading roughly flat amid broader market dynamics.

5 de ago. de 2026, 19:16 UTC

Correlated Moves

Bio-Techne Corp's shares are lower today, reflecting declines in the Russell 2000 Index. The stock remains near the upper end of its one-month trading range.

4 de ago. de 2026, 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are higher in after-market trading, buoyed by positive sentiment from U.S.-Iran negotiations and gains in major technology stocks.

3 de ago. de 2026, 19:26 UTC

Correlated Moves

Bio-Techne Corp is advancing, reflecting broader market positivity amid gains in major tech stocks and falling energy prices. The stock is near its one-month trading range high.

31 de jul. de 2026, 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are lower in after-market trading amid a broader market downturn, reflecting negative sentiment impacting price action.

30 de jul. de 2026, 18:26 UTC

Correlated Moves

Bio-Techne Corp is trading roughly flat as the broader market recovers from declines, influenced by rising Treasury yields and inflation concerns.

29 de jul. de 2026, 22:03 UTC

Bio-Techne Corp shares are lower in after-market hours, reflecting a decline since Wednesday's close amid cautious market sentiment and geopolitical tensions.

20 de jul. de 2026, 18:01 UTC

Bio-Techne Corp shares are lower today, with no specific news identified. Broader market pressures include rising yields and inflation concerns linked to oil prices.

Comparação entre Pares

Variação de preço

Bio-Techne Corp Previsão

Preço-alvo

By TipRanks

-1.86% parte inferior

Previsão para 12 meses

Média 70.89 USD  -1.86%

Máximo 73 USD

Mínimo 62 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Bio-Techne Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

11 ratings

1

Comprar

10

Manter

0

Vender

Sentimento

By Acuity

291 / 340 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat